Table 1 Tumor features and CTC detection of HCC patients.
Patient ID | Blood Collection Time | BCLC stage | Number of lesions | Largest lesion size (cm) | CTC (per 5 ml) | CTNNB1 Codon 32–37 Mutation% | |
|---|---|---|---|---|---|---|---|
Plasma cfDNA | CTC DNA | ||||||
HCCAK503 | Pre-treatment | C | 10 | 5.6 | 16 | NA | NA |
HCCAK516 | Pre-transplantation | A | 1 | 3.3 | 11 | NA | NA |
HCCAK519 | Pre-transplantation | B | 3 | 3.4 | 2 | NA | NA |
HCCAK484 | Post-TACE | B | 1 | 2.8 | 2 | NA | NA |
HCCAK521* | Pre-TACE | B | 4 | 4 | 6 | BLOD (QNS)+ | 1.14%, 1.25% |
HCCAK526* | Pre-TACE | B | 1 | 6.4 | 28 | BLOD (QNS)+ | 0.48%, 1.12% |
HCCAK505 | Post-TACE | 0 | 1 | 1.6 | 11 | NA | NA |
HCCAK520 | Pre-TACE | A | 1 | 3 | 6 | NA | NA |
HCCAK493 | Pre-TACE | B | 1 | 5.3 | 3 | NA | NA |
HCCAK489 | Pre-transplantation | B | 1 | 2.4 | 7 | NA | NA |
